Question from Deputy Ken O’Flynn - PQ 39837-26
Deputy O'Flynn asked about the average period between European Medicines Agency authorisation and final reimbursement decision for orphan medicines.
- Published date:
- :
Browse and read HSE's latest publications, which include strategic plans, reports, official policies and codes, Parliamentary Question (PQ) responses, and board meeting minutes.
Deputy O'Flynn asked about the average period between European Medicines Agency authorisation and final reimbursement decision for orphan medicines.
Deputy O'Flynn asked about the reimbursement assessment process for omaveloxolone (skyclarys). Read the HSE response.
Deputy Ó Murchú asked about the home care waiting lists and waiting times across east Meath. Read the HSE response.
Deputy O'Flynn asked if the HSE records instances of people presenting to addiction services who require mental health intervention for dual diagnosis condition
Deputy Ó Murchú asked about the home care waiting lists and waiting times across north Meath and Ardee. Read the HSE response.
Deputy O'Flynn asked if any comparative analysis of orphan drug reimbursement timelines and approval rates against comparable European jurisdictions.
Deputy Ó Mucú asked about the home care waiting lists and waiting times across central Meath. Read the HSE response.
Deputy Ó Murchú asked for a breakdown of home care waiting lists and waiting times across southwest Meath. Read the HSE response.
Deputy O'Flynn asked if the HSE maintains a centralised national system relating to agency or locum healthcare workers across HSE-funded services.
Deputy O'Flynn asked about the number of orphan or ultra-rare disease medicines which received a negative reimbursement recommendation. Read the HSE response.